Hyundai Pharmaceutical Co. Ltd. secured rights to market Acerus Pharmaceuticals Corp.'s Natesto treatment in South Korea.

Financial terms of the agreement were not disclosed, though Acerus said it will receive an upfront payment followed by milestone-related payments upon regulatory approval of the product in South Korea.

The nasal gel is already available in U.S. and Canada for hormone-related deficiencies.